Toxicological profile of IQG-607 after single and repeated oral administration in minipigs: An essential step towards phase I clinical trial.
Rodrigues-Junior, Valnês S; Cintra, Luciana; Machado, Pablo; Dadda, Adílio; Basso, Luiz Augusto; Mafra, Ana Carolina Cintra Nunes; Campos, Alexandre Holthausen; Campos, Maria Martha; Santos, Diógenes Santiago.
Regul Toxicol Pharmacol
; 90: 78-86, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28838610
Preclinical pharmacokinetic profiling of IQG-607, a potential oral metallodrug to treat tuberculosis.
Spray-dried fucoidan microparticles for pulmonary delivery of antitubercular drugs.
Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients.
ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
Mechanism of isoniazid-induced hepatotoxicity: then and now.
3D-Printed Isoniazid Tablets for the Treatment and Prevention of Tuberculosis-Personalized Dosing and Drug Release.
Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects.
Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.
Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.